Role of clinical pathologies in myocardial injury following ischaemia and reperfusion

Cardiovascular Research

Volumn 61, Issue 3, 2004, Pages 512-521

  Galiñanes, Manuel ^a   Fowler, Alan G ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Diabetes; Heart failure; Hypercholesterolaemia; Hypertension; Hypertrophy; Reperfusion injury

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INTERLEUKIN 6; NITRIC OXIDE; STRESS ACTIVATED PROTEIN KINASE;

CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; HEART FAILURE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; RISK FACTOR;

ANIMALS; CARDIOMEGALY; DIABETES COMPLICATIONS; DIABETES MELLITUS; HEART FAILURE, CONGESTIVE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM;

EID: 1142309737     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2003.11.028     Document Type: Review

References (177)

1. Hammoud T., Tanguay J.F., Bourassa M.G. Management of coronary artery disease: therapeutic options in patients with diabetes. J. Am. Coll. Cardiol. 36:2000;355-365.
2. Stamler J., Vaccaro O., Neaton J.D., Wentworth D. Diabetes, other risk factors and 12-year mortality from men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 16:1993;434-444.
3. Kannel W. Lipids, diabetes and coronary heart disease: insights from the Framingham Study. Am. Heart J. 110:1985;1100-1107.
4. Jacoby R.M., Nesto R.W. Acute myocardial infarction in the diabetic patient: pathophysiology, clinical course and prognosis. J. Am. Coll. Cardiol. 20:1992;736-744.
5. Woodfield S.L., Lundergan C.F., Reiner J.S.et al. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-1 experience. J. Am. Coll. Cardiol. 28:1996;1661-1669.
6. Zuanetti G., Latini R., Maggioni A.P., Santoro L., Franzosi M.G. Influence of diabetes on mortality in acute myocardial infarction: data from GISSI-2 study. J. Am. Coll. Cardiol. 22:1993;1788-1794.
7. Smith L.R., Harell F.E. Jr., Rankin J.S.et al. Determinants of early versus late cardiac death in patients undergoing coronary bypass graft surgery. Circulation. 84(suppl III):1991;III-245-III-253.
8. Alderman E.L., Corley S.D., Fisher L.D.et al. Five-year angiographic follow up of factors associated with progression of coronary artery disease in the Coronary Artery Surgery Study (CASS). The CASS Participating Investigators and Staff. J. Am. Coll. Cardiol. 22:1993;1141-1154.
9. Herlitz J., Wognsen G.B., Emanuelson H.et al. Mortality and morbidity in diabetic and non-diabetic patients during a 2-year period after coronary artery bypass grafting. Diabetes Care. 19:1996;698-703.
10. Rao V., Ivanov J., Weisel R.D., Ikonomidis J.S., Christakis G.T., David T.E. Predictors of low cardiac output syndrome after coronary artery bypass. J. Thorac. Cardiovasc. Surg. 112:1996;38-51.
11. Barsness G.W., Peterson E.D., Ohman E.M. Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. Circulation. 96:1997;2551-2556.
12. Andersen B., Goldsmith G.H., Spagnolo P.J. Neutrophil adhesive dysfunction in diabetes mellitus: the role of cellular and plasma factors. J. Lab. Clin. Med. 111:1988;275-285.
13. McDonagh P., Hokoma J.Y. Microvascular perfusion and transport in the diabetic heart. Microcirculation. 7:2000;163-181.
14. Hearse D.J., Stewart D.A., Chain E.B. Diabetes and the survival and recovery of the anoxic myocardium. J. Mol. Cell. Cardiol. 7:1975;397-415.
15. Kusama Y., Hearse D.J., Avkiran M. Diabetes and susceptibility to reperfusion induced ventricular arrhythmias. J. Mol. Cell. Cardiol. 24:1992;411-421.
16. Ghosh S., Standen N.B., Galiñanes M. Failure to precondition pathological myocardium. J. Am. Coll. Cardiol. 37:2001;711-718.
17. Hassouna A., Loubani M., Fowler A.G., Standen N.B., Galiñanes M. Can the diabetic heart be preconditioned? Role of mitoKatp channels, PKC and p38MAPK. Circulation. 106(Suppl. II):2002;245.
18. Haider B., Ahmed S.S., Moschos C.B., Oldewurtel H.A., Regan T.J. Myocardial function and coronary blood flow response to acute ischemia in chronic canine diabetes. Circ. Res. 40:1977;577-583.
19. Feuvray D., Idell-Wenger J.A., Neely J.R. Effects of ischemia on rat myocardial function and metabolism in diabetes. Circ. Res. 44:1979;322-329.
20. Lopaschuk G.D., Spafford M. Response of isolated working hearts from acutely and chronically diabetic rats to fatty acids and carnitine palmitoyltransferase I inhibition during reduction of coronary flow. Circ. Res. 65:1989;378-387.
21. Liu Y., Thornton J.D., Cohen M.V., Downey J.M., Schaffer S.W. Streptozotocin-induced non-insulin-dependent diabetes protects the heart from infarction. Circulation. 88:1993;1273-1278.
22. 2+ metabolism. Circ. Res. 62:1988;931-940.
23. Lopaschuk G.D., Saddik M., Barr R., Huang L., Barker C.C., Muzyka R.A. Effects of high levels of fatty acids on functional recovery of ischemic hearts from diabetic rats. Am. J. Physiol. 263:1992;E1046-E1053.
24. Broderick T.L., Quinney H.A., Lopaschuk G.D. L-Carnitine increase glucose metabolism and mechanical function following ischemia in diabetic rat heart. Cardiovasc. Res. 29:1995;373-378.
25. Lopaschuk G.D., Belke D.B., Gamble J., Itoi T., Schönekess B.O. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim. Biophys. Acta. 1213:1994;263-276.
26. Mildenberger R.R., Bar-Shlomo B., Druck M.N.et al. Clinically unrecognized ventricular dysfunction in young diabetic patients. J. Am. Coll. Cardiol. 4:1984;234-238.
27. Borow K.M., Jaspan J.B., Williams K.A., Neumann A., Wolonski-Walley P., Lang R.M. Myocardial mechanics in young adult patients with diabetes mellitus: effects of altered load, inotropic state and dynamic exercise. J. Am. Coll. Cardiol. 15:1990;1508-1517.
28. Paulson D.J. The diabetic heart is more sensitive to ischemic injury. Cardiovasc. Res. 34:1997;104-112.
29. Feuvray D., Lopaschuk G.D. Controversies on the sensitivity of the diabetic heart to ischemic injury: the sensitivity of the diabetic heart to ischemic injury is decreased. Cardiovasc. Res. 34:1997;113-120.
30. Cohen M.V. Free radicals in ischemic and reperfusion myocardial injury: is this the time for clinical trials? Ann. Intern. Med. 111:1989;918-931.
31. Wohaieb S.A., Godin D.V. Alterations in free radical tissue-defense mechanisms in streptozotocin-induced diabetes in rat: effects of insulin treatment. Diabetes. 35:1987;1014-1018.
32. Liu X., Kim C.N., Yang J., Jemmerson R., Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell. 86:1996;147-157.
33. Green D.R., Reed J.C. Mitochondria and apoptosis. Science. 281:1998;1309-1312.
34. Crompton M. The mitochondrial permeability transition pore and its role in cell death. Biochem. J. 341:1999;233-249.
35. 2+ release. Arch. Biochem. Biophys. 195:1979;468-477.
36. 2+-dependent pore activated by oxidative stress in heart mitochondria. Biochem. J. 245:1987;915-918.
37. Halestrap A.P., Connern C.P., Griffiths E.J., Kerr P.M. Cyclosporin A binding to mitochondrial cyclophilin inhibits the permeability transition pore and protects hearts from ischaemia/reperfusion injury. Mol. Cell. Biochem. 174:1997;167-172.
38. Zamzami N., Marchetti P., Castedo M.et al. Inhibitors of permeability transition interfere with the disruption of the mitochondrial transmembrane potential during apoptosis. FEBS Lett. 384:1996;53-57.
39. Lemasters J.J., Nieminen A.L., Qian T.et al. The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. Biochem. Biophys. Acta. 1366:1998;177-196.
40. Capes S.E., Hunt D., Malberg K.et al. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systemic overview. Lancet. 355:2000;773-778.
41. Lorenzi M., Cagliero E., Toledo S. Glucose toxicity for human endothelial cells in culture. Diabetes. 34:1985;621-627.
42. 2-terminal kinase and caspase-3. Circulation. 101:2000;2618-2624.
43. Esposito K., Nappo F., Marfella R.et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 106:2002;2067-2072.
44. Pickup J.C., Chusney G.D., Thomas S.M.et al. Plasma interleukin-6, tumor necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci. 67:2000;291-300.
45. Arnalich F., Hernanz A., Lopez-Maderuelo D.et al. Enhanced acute-phase response and oxidative stress in older adults with type II diabetes. Horm. Metab. Res. 32:2000;407-412.
46. Kado S., Nagase T., Nagata N.et al. Circulating levels of interleukin-6, its soluble receptor and interleukin-6/interleukin-6 receptor complexes in patients with type 2 diabetes mellitus. Acta Diabetol. 36:1999;67-72.
47. Pradhan A.D., Manson J.A.E., Rifai N.et al. C-reactive protein, interleukin-6, and risk of developing type 2 diabetes mellitus. JAMA. 286:2001;327-334.
48. Guha M., Bai W., Nadler J.L.et al. Molecular mechanisms of tumor necrosis factor alpha gene expression in monocytic cells via hyperglycemia-induced oxidant stress-dependent and -independent pathways. J. Biol. Chem. 275:2000;17728-17739.
49. Panes J., Kurose I., Rodriguez-Vaca D., Anderson D.C., Miyasaka M., Tso P.et al. Diabetes exacerbates inflammatory responses to ischaemia-reperfusion. Circulation. 93:1996;161-167.
50. Hernandez-Pando R., Schon T., Orozco E.H., Serafin J., Estrada-Garcia I. Expression of inducible nitric oxide synthase and nitrotyrosine during the evolution of experimental pulmonary tuberculosis. Exp. Toxicol. Pathol. 53:2001;257-265.
51. Heeringa P., Steenbergen E., van Goor H. A protective role for endothelial nitric oxide synthase (eNOS) in glomerulonephritis. Kidney Int. 61:2002;822-825.
52. Rosen P., Du X., Sui G.Z. Molecular mechanisms of endothelial dysfunction in the diabetic heart. Adv. Exp. Med. Biol. 498:2001;75-86.
53. Chan N.N., Chan J.C. Asymetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome? Diabetologia. 45:2002;1609-1616.
54. Panza J.A. Endothelial dysfunction in essential hypertension. Clin. Cardiol. 20:1997;II-26-II33.
55. Feron O., Dessy C., Moniotte S., Desager J.P., Balligand J.L. Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. J. Clin. Invest. 103:1999;897-905.
56. Arnal J.F., Dinh-Xuan A.T., Pueyo M., Darblade B., Rami J. Endothelial-derived nitric oxide and vascular physiology and pathology. Cell. Mol. Life Sci. 55:1999;1078-1087.
57. De Vriese A.S., Stoenoiu M.S., Elger M.et al. Diabetes-induced microvascular dysfunction in the hydronephrotic kidney: role of nitric oxide. Kidney Int. 60:2001;202-210.
58. Beresewicz A., Karwatowska-Prokopczuk E., Lewartowski B., Cedro-Ceremuazynska K. A protective role of nitric oxide in isolated ischaemic/reperfused rat heart. Cardiovasc. Res. 30:1995;1001-1008.
59. Weyrich A.S., Ma X.L., Lefer A.M. The role of L-arginine in ameliorating reperfusion injury after myocardial ischemia in the cat. Circulation. 86:1992;279-288.
60. Lefer D.J., Nakanishi K., Johnston W.E., Vinten-Johansen J. Antineutrophil and myocardial protecting actions of a novel nitric oxide donor after acute myocardial ischemia and reperfusion of dogs. Circulation. 88:1993;2337-2350.
61. Flogel U., Decking U.K., Godecke A., Schrader J. Contribution of NO to ischemia-reperfusion injury in the saline-perfused heart: a study in endothelial NO synthase knockout mice. J. Mol. Cell. Cardiol. 31:1999;827-836.
62. Jones S.P., Girod W.G., Palazzo A.J.et al. Myocardial ischemia-reperfusion injury is exacerbated in absence of endothelial cell nitric oxide synthase. Am. J. Physiol. 276:1999;H1567-H1573.
63. Kanno S., Lee P.C., Zhang Y.et al. Attenuation of myocardial ischemia/reperfusion injury by superinduction of inducible nitric oxide synthase. Circulation. 101:2000;2742-2748.
64. Woolfson R.G., Patel V.C., Neild G.H., Yellon D.M. Inhibition of nitric oxide synthesis reduces infarct size by an adenosine-dependent mechanism. Circulation. 91:1995;1545-1551.
65. Poon B.Y., Raharjo E., Patel K.D., Tavener S., Kubes P. Complexity of inducible nitric oxide synthase: cellular source determines benefit versus toxicity. Circulation. 108:2003;1107-1112.
66. + channels. Circ. Res. 81:1997;1072-1082.
67. + channels and myocardial preconditioning. Circ. Res. 84:1999;973-979.
68. Liu Y., Sato T., O'Rourke B., Marban E. Mitochondrial ATP-dependent potassium channels: novel effectors of cardioprotection? Circulation. 97:1998;2463-2469.
69. Pain T., Yang X.M., Critz S.D.et al. Opening of mitochondrial K(ATP) channels triggers the preconditioned state by generating free radicals. Circ. Res. 87:2000;460-466.
70. Fryer R.M., Hsu A.K., Gross G.J. Mitochondrial K(ATP) channel opening is important during index ischemia and following myocardial reperfusion in ischemic preconditioned rat hearts. J. Mol. Cell. Cardiol. 33:2001;831-834.
71. Smith J.M., Wahler G.M. ATP-sensitive potassium channels are altered in ventricular myocytes from diabetic rats. Mol. Cell. Biochem. 158:1996;43-51.
72. Tune J.D., Mallet R.T., Downey H.F. Insulin improves contractile function during moderate ischemia in canine left ventricle. Am. J. Physiol. 274:1998;H1574-H1581.
73. Doenst T., Guthrie P.H., Chemnitius J.M., Zech R., Taegmeyer H. Fasting, latate, and insulin improve ischemia tolerance in rat heart: a comparison with ischemic precondiioning. Am. J. Physiol. 270:1996;H1607-H1615.
74. Scognamiglio R., Avogaro A., Vigili de Kreutzenberg S.et al. Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes. Diabetes. 51:2002;808-812.
75. Zhu P., Li L., Ya X., Greyson C., Schwatrz G.G.H. Glucose-insulin- potassium preserves systolic and diastolic function in ischemia and reperfusion in pigs. Am. J. Physiol. Heart Circ. Physiol. 278:2000;H595-H603.
76. Jonassen A.K., Aasum E., Riemersma R.A., Mjos O.D., Larsen T.S. Glucose-insulin-potassium reduces infarct size when administered during reperfusion. Cardiovasc. Drugs Ther. 14:2000;615-623.
77. Malmberg K., Ryden L., Efendic S.et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J. Am. Coll. Cardiol. 26:1995;57-65.
78. Kannel W.P., Castelli W.P., Gordon T., McNamara P. Serum cholesterol, lipoproteins and risk of coronary heart disease: the Framingham study. Ann. Intern. Med. 74:1971;1-12.
79. Keys A. Coronary heart disease in seven countries. Circulation. 41(Suppl. I):1970;I-1-I-8.
80. Golino P., Maroko P.R., Carew T.E. The effect of acute hypercholesterolaemia on myocardial infarct size and the no-reflow phenomenon during coronary occlusion-reperfusion. Circulation. 75:1987;292-298.
81. Tilton R.G., Cole P.A., Zions J.D.et al. Increased ischemia-reperfusion injury to the heart associated with short-term, diet-induced hypercholesterolemia in rabbits. Circ. Res. 60:1987;551-559.
82. Girod W.G., Jones S.P., Sieber N., Aw T.Y., Lefer D.J. Effects of hypercholesterolemia on myocardial ischemia-reperfusion injury in LDL receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 19:1999;2776-2781.
83. Le Grand B., Vie B., Faure P., Degryse A.D., Mouillard P., John G.W. Increased resistance to ischaemic injury in the isolated perfused atherosclerotic heart of the cholesterol-fed rabbit. Cardiovasc. Res. 30:1995;689-696.
84. Lefer A.M., Ma X.L. Decreased basal nitric oxide release in hypercholesterolemia increases neutrophil adherence to rabbit coronary artery endothelium. Arterioscler. Thromb. 13:1993;771-776.
85. Andrews H.E., Bruckdorfer K.R., Dunn R.C., Jacobs M. Low-density lipoproteins inhibit endothelium-dependent relaxation in rabbit aorta. Nature. 327:1987;237-239.
86. Girerd X.J., Hirsch A.T., Cooke J.P., Dzau V.J., Creager M.A. L-Arginine augments endothelium-dependent vasodilation in cholesterol-fed rabbits. Circ. Res. 67:1990;1301-1308.
87. Rossitch E., Alexander E., Black P.M., Cooke J.P. L-Arginine normalizes endothelial function in cerebral vessels from hypercholesterolemic rabbits. J. Clin. Invest. 87:1991;1295-1299.
88. Gilligan D.M., Guetta B., Panza J., Garcia C.E., Quyyumi A.A., Cannon R.O. Selective loss of microvascular endothelial function in human hypercholesterolemia. Circulation. 90:1994;35-41.
89. Drexler H., Zeiher A.M., Meinzer K., Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolemic patients by L-arginine. Lancet. 338:1991;1546-1550.
90. Kurose I., Argenbright L.W., Anderson D.C., Tolley J., Miyasaka M., Granger D.N. Reperfusion-induced leukocyte adhesion and vascular protein leakage in normal and hypercholesterolemic rats. Am. J. Physiol. 273:1997;H854-H860.
91. Lefer D.J., Nakanishi K., Johnston W.E., Vinten-Johansen J. Antineutrophil and myocardial protecting actions of a novel nitric oxide donor after acute myocardial ischemia and reperfusion in dogs. Circulation. 88:1993;2337-2350.
92. Ma X.L., Weyrich A.S., Lefer D.J., Lefer A.M. Diminished basal nitric oxide release after myocardial ischemia and reperfusion promotes neutrophil adherence to coronary endothelium. Circ. Res. 72:1993;403-412.
93. Hoshida S., Yamashita N., Igarashi J.et al. A nitric oxide donor reverses myocardial injury in rabbits with acute hypercholesterolemia. J. Pharmacol. Exp. Ther. 278:1996;741-746.
94. White C.R., Darley-Usmar V., Berrington W.R.et al. Circulating plasma xanthine oxidase contributes to vascular dysfunction in hypercholesterolemic rabbits. Proc. Natl. Acad. Sci. U. S. A. 93:1996;8745-8749.
95. Kurose I., Wolf R.E., Grisham M.B., Granger D.N. Hypercholesterolemia enhances oxidant production in mesenteric venules exposed to ischaemia-reperfusion. Arterioscler. Thromb. Vasc. Biol. 18:1998;1583-1588.
96. Xiao L., Pimentel D.R., Wang J., Singh K., Colucci W.S., Sawyer D.B. Role of reactive oxygen species and NAD(P)H oxidase in alpha(1)-adrenoceptor signaling in adult rat cardiac myocytes. Am. J. Physiol. Cell Physiol. 282:2002;C926-C934.
97. Downey J.M., Miura T., Eddy L.J.et al. Xanthine oxidase is not a source of free radicals in the ischemic rabbit heart. J. Mol. Cell. Cardiol. 19:1987;1053-1060.
98. Sorescu D., Griendling K.K. Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure. Congest. Heart Fail. 8:2002;132-140.
99. Laufs U., La Fata V., Plutzky J.et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 97:1998;1129-1135.
100. Pruefer D., Scalia R., Lefer A.M. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Aterioscler. Thromb. Vasc. Biol. 19:1999;2894-2900.
101. Scalia R., Gooszen M.E., Jones S.P.et al. Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein E-deficient mice. Circulation. 103:2001;2598-2603.
102. Lefer A.M., Campbell B., Shin Y.K.et al. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation. 100:1999;178-184.
103. Kureishi Y., Luo Z., Shiojima I.et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med. 6(9):2000;1004-1010.
104. Ledoux S., Laouari D., Essig M.et al. Lovastatin enhances ecto-5′-nucleotidase activity and cell surface expression in endothelial cells: implication of rho-family GTPases. Circ. Res. 90:2002;420-427.
105. Cambien F., Poirier O., Lecerf L.et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 359:1992;641-644.
106. Raynolds M.V., Bristow M.R., Bush E.W.et al. Angiotensin-converting enzyme DD genotype in patients with ischemic or idiopathic dilated cardiomyopathy. Lancet. 342:1993;1073-1075.
107. Alderman M.H., Madhavan S., Ooi W.L., Cohen H., Sealy J.E., Laragh J.H. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N. Engl. J. Med. 324:1991;1098-1104.
108. Fleetwood G., Boutinet S., Meier M., Wood J.M. Involvement of the renin-angiotensin system in ischemic damage and reperfusion arrhythmias in the isolated perfused rat heart. J. Cardiovasc. Pharmacol. 17:1991;351-356.
109. Sun Y., Weber K.T. Angiotensin II receptor binding following myocardial infarction in the rat. Cardiovasc. Res. 28:1994;1623-1628.
110. Yang B.C., Phillips M.I., Ambuehl P.E.J., Shen L.P., Mehta P., Mehta J.L. Increase in angiotensin II type 1 receptor expression immediately following ischemia-reperfusion in isolated rat hearts. Circulation. 96:1997;922-926.
111. 31P nuclear magnetic resonance. J. Cardiovasc. Pharmacol. 24:1994;573-586.
112. Yoshiyama M., Kim S., Yamagishi H.et al. Cardioprotective effect of the angiotensin II type 1 receptor antagonist TCV-116 on ischemia-reperfusion injury. Am. Heart J. 128:1994;1-6.
113. Harada K., Sugaya T., Mura K., Yazaki Y., Komuro I. Angiotensin II type 1A receptor knockout mice display less left ventricular remodelling and improved survival after myocardial infarction. Circulation. 100:1999;13-21.
114. Thomas G.P., Ferrier G.R., Howlett S.E. Losartan exerts antiarrythmic activity independent of angiotensin II receptor blockade in simulated ventricular ischemia and reperfusion. J. Pharmacol. Exp. Ther. 278:1996;1090-1097.
115. Lee Y.M., Peng Y.Y., Ding Y.A., Yen M.H. Losartan attenuates myocardial ischemia-induced ventricular arrhythmias and reperfusion injury in spontaneously hypertensive rats. Am. J. Hypertens. 10:1997;852-858.
116. Weidenbach R., Schulz R., Gres P., Behrends M., Post H., Heusch G. Enhanced reduction of myocardial infarct size by combined ACE inhibition and AT(1)-receptor antagonism. Br. J. Pharmacol. 131:2000;138-144.
117. Klein L., O'Connor C.M., Gattis W.A.et al. Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations. Am. J. Cardiol. 91(9A):2003;18F-40F.
118. Teo K.K., Yusuf S., Pfeffer M.et al. Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet. 360:2002;1037-1043.
119. Laursen J.B., Rajagopalan S., Galis Z.et al. Role of superoxide in angiotensin-II-induced but not catecholamine-induced hypertension. Circulation. 95:1997;588-593.
120. Lerman L.O., Nath K.A., Rodriguez-Porcel M.et al. Increased oxidative stress in experimental hypertension. Hypertension. 37:2001;541-546.
121. Suzuki H., DeLano F.A., Parks D.A.et al. Xanthine oxidase activity associated with arterial blood pressure in spontaneously hypertensive rats. Proc. Natl. Acad. Sci. U. S. A. 95:1998;4754-4759.
122. Swei A., Lacy F., DeLano F.A., Schmid-Schonbein G.W. Oxidative stress in the Dahl hypertensive rat. Hypertension. 30:1997;1628-1633.
123. Minuz P., Patrignani P., Gaino S.et al. Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. Circulation. 106:2002;2800-2805.
124. Schmid-Schonbein G.W., Seiffge D., DeLano F.A., Shen K., Zweifach B.W. Leukocyte counts and activation in spontaneously hypertensive and normotensive rats. Hypertension. 17:1995;323-330.
125. Shen K., DeLano F.A., Zweifach B.W., Schmid-Schonbein G.W. Circulating leukocyte counts, activation, and degranulation in Dahl hypertensive rats. Circ. Res. 76:1995;276-283.
126. Arndt H., Smith C.W., Granger D.N. Leukocyte-endothelial cell adhesion in spontaneously hypertensive and normotensive rats. Hypertension. 21:1993;667-673.
127. Suzuki H., Schmid-Schonbein G.W., Suematsu M.et al. Impaired leukocyte-endothelial cell interaction in spontaneously hypertensive rats. Hypertension. 24:1994;719-727.
128. Kurose I., Wolf R., Cerwinka W., Granger D.N. Microvascular responses to ischemia/reperfusion in normotensive and hypertensive rats. Hypertension. 34:1999;212-216.
129. Levy D., Anderson K.M., Savage D.D., Kannel W.B., Christiansen J.C., Castelli W.P. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann. Intern. Med. 108:1988;7-13.
130. Grossman W., Jones D., McLaurin L.P. Wall stress and patterns of hypertrophy in the human heart. J. Clin. Invest. 56:1975;56-64.
131. Hearse D.J., Stewart S.A., Green D.G. Myocardial susceptibility to ischemic damage: a comparative study of disease models in the rat. Eur. J. Cardiol. 7:1978;437-450.
132. Menasche P., Grousset C., Apstein C.S., Marotte F., Mouas C., Piwnica A. Increased injury of hypertrophied myocardium with ischemic arrest: preservation with hypothermia and cardioplegia. Am. Heart J. 110:1985;1204-1209.
133. Gaasch W.H., Zile M.R., Hoshino P.K., Weinberg E.O., Rhodes D.R., Apstein C.S. Tolerance of the hypertrophic heart to ischemia: studies in compensated and failing dog hearts with pressure overload hypertrophy. Circulation. 81:1990;1644-1653.
134. Anderson P.G., Allard M.F., Thomas G.D., Bishop S.P., Digerness S.B. Increased ischemic injury but decreased hypoxic injury in hypertrophied rat hearts. Circ. Res. 67:1990;948-959.
135. Holtz J., Restorff W.V., Bard P., Bassenge E. Transmural distribution of myocardial blood flow and of coronary reserve in canine left ventricular hypertrophy. Basic Res. Cardiol. 72:1977;286-292.
136. Batra S., Rakusan K., Campbell S.E. Geometry of capillary networks in hypertrophied rat hearts. Microvasc. Res. 41:1991;29-40.
137. Buja L.M., Hagler H.K., Willerson J.T. Altered calcium homeostasis in the pathogenesis of myocardial ischemic and hypoxic injury. Cell Calcium. 8:1988;205-217.
138. Nayler W.G. Calcium and cell death. Eur. Heart J. 4:1983;33-41. [Suppl].
139. Allard M.F., Flint J.D., English J.C.et al. Calcium overload during reperfusion is accelerated in isolated hypertrophied rat hearts. J. Mol. Cell. Cardiol. 26:1994;1551-1563.
140. 2+ exchange. Circ. Res. 65:1989;1045-1056.
141. Lauerma K., Saeed M., Wendland M.F., Derugin N., Yu K.K., Higgins C.B. Verapamil reduces the size of reperfused ischemically injured myocardium in hypertrophied rat hearts as assessed by magnetic resonance imaging. Am. Heart J. 131:1996;14-23.
142. Taylor A.L., Winter R., Thandroyen F.et al. Potentiation of reperfusion-associated ventricular fibrillation by left ventricular hypertrophy. Circ. Res. 67:1990;501-509.
143. Baxter G.F., Yellon D.M. Regression of left ventricular hypertrophy and susceptibility to reperfusion-induced arrhythmias after DOCA-salt hypertension in the rat. Cardioscience. 3:1992;245-250.
144. Baxter G.F., Yellon D.M. Attenuation of reperfusion-induced ventricular fibrillation in the rat isolated hypertrophied heart by preischemic diltiazem treatment. Cardiovasc. Drug Ther. 7:1993;225-231.
145. Keung E.C. Calcium current is increased in isolated adult myocytes from hypertrophied rat myocardium. Circ. Res. 64:1989;753-763.
146. Kleiman R.B., Houser S.R. Calcium currents in normal and hypertrophied isolated feline ventricular myocytes. Am. J. Physiol. 255:1988;H1434-H1442.
147. Aronson R.S. After potentials and triggered activity in hypertrophied myocardium from rats with renal hypertension. Circ. Res. 48:1981;720-727.
148. Kannel W.B. Prevalence and natural history of electrocardiographic left ventricular hypertrophy. Am. J. Med. 75:1983;4-11.
149. Friedman M., Manwaring J.H., Rosenman R.H., Donlon G., Ortega P., Grube S.M. Instantaneous and sudden deaths: clinical and pathological differentiation in coronary artery disease. JAMA. 225:1973;1319-1328.
150. Wambolt R.B., Henning S.L., English D.R., Bondy G.P., Allard M.F. Regression of cardiac hypertrophy normalizes glucose metabolism and left ventricular function during reperfusion. J. Mol. Cell. Cardiol. 29:1997;939-948.
151. Schonekess B.O., Allard M.F., Lopaschuk G.D. Recovery of glycolysis and oxidative metabolism during postischemic reperfusion of hypertrophied rat hearts. Am. J. Physiol. 271:1996;H798-H805.
152. Lopaschuk G.D., Wambolt R.B., Barr R.L. An imbalance between glycolysis and glucose oxidation is a possible explanation for the detrimental effects of high levels of fatty acid during aerobic perfusion of ischemic hearts. J. Pharmacol. Exp. Ther. 264:1993;135-144.
153. Stanley W.C., Lopaschuk G.D., Hall J.L., McCormack J.G. Regulation of myocardial carbohydrate metabolism under normal and ischemic conditions: potential for pharmacological interventions. Cardiovasc. Res. 33:1997;243-257.
154. McVeigh J.J., Lopaschuk G.D. Dichloroacetate stimulation of glucose oxidation improves recovery of ischemic rat heart. Am. J. Physiol. 259:1990;H1079-H1085.
155. Taegtmeyer H., Overturf M.L. Effects of moderate hypertension on cardiac function and metabolism in the rabbit. Hypertension. 11:1988;416-426.
156. Wambolt R.B., Lopaschuk G.D., Brownsey R.W., Allard M.F. Dichloroacetate improves postischemic function of hypertrophied rat hearts. J. Am. Coll. Cardiol. 36:2000;1378-1385.
157. Allard M.F., Emanuel P.G., Russell J.A., Bishop S.P., Digerness S.B., Anderson P.G. Preischemic glycogen reduction or inhibition of glycolysis (2-deoxyglucose) improve postischemic functional recovery of hypertrophied rat hearts. Am. J. Physiol. 267:1994;H66-H74.
158. Fabiato A., Fabiato F. Effects of pH on the myofilaments and sarcoplasmic reticulum of skinned cells from cardiac and skeletal muscles. J. Physiol. 276:1978;233-255.
159. Lazdunski M., Frelin C., Vigne P. The sodium/hydrogen exchange system in cardiac cells: its biochemical and pharmacological properties and its role in regulating internal concentrations of sodium and internal pH. J. Mol. Cell. Cardiol. 17:1985;1029-1042.
160. Golden A.L., Bright J.M., Pohost G.M., Pike M.M. Ischemic dysfunction and impaired recovery in hypertensive hypertrophied hearts is associated with exaggerated intracellular sodium accumulation. Am. J. Hypertens. 7:1994;745-754.
161. Shimada Y., Gunasegaram S., Yokoyama H., Avkiran M. Inhibition of angiotensin-converting enzyme reduces susceptibility of hypertrophied rat myocardium to ventricular fibrillation. Circ. J. 66:2002;1045-1053.
162. + ATPase activity abd ouabain binding sites in sarcolemmal prepared from hearts of spontaneously hypertensive rats. Hypertension. 5:1983;682-699.
163. 2+ exchanger in response to cardiac pressure overload. Am. J. Physiol. 265:1993;H1024-H1029.
164. Swynghedauw B., Delcayre C., Cheav S.L., Callens-El Amrani F. Biological basis of diastolic dysfunction of the hypertensive heart. Eur. Heart J. 13 (D):1992;2-8.
165. Arai M., Matsui H., Periasamy M. Sarcoplasmic reticulum gene expression in cardiac hypertrophy and heart failure. Circ. Res. 74:1994;555-564.
166. Bril A., Forest M.C., Gout B. Ischemia and reperfusion-induced arrhythmias in rabbits with chronic heart failure. Am. J. Physiol. 261:1991;H301-H307.
167. McMurray J., Chopra M., Abdullah I.et al. Evidence of oxidative stress in chronic heart failure in humans. Eur. Heart J. 14:1993;1493-1498.
168. Belch J.J.F., Bridges A.B., Scott N.et al. Oxygen free radicals and congestive heart failure. Br. Heart J. 65:1991;245-248.
169. Dhalla A.K., Singal P.K. Antioxidant changes in hypertrophied and failing guinea pig hearts. Am. J. Physiol. 266:1994;H1280-H1285.
170. Ide T., Tsutsui H., Kinugawa S.et al. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ. Res. 85:1999;357-363.
171. Ide T., Tsutsui H., Kinugawa S.et al. Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium. Circ. Res. 86:2000;152-157.
172. Maekawa N., Wada H., Saito K.et al. Myocardial ischemia/reperfusion injury in mice lacking tumor necrosis factor-α Circulation. 102:2000;II-77.
173. McTiernan C.F., Feldman A.M. The role of tumor necrosis factor alpha in the pathophysiology of congestive heart failure. Curr. Cardiol. Rep. 2:2000;189-197.
174. Gudz T.I., Tserng K.Y., Hoppel C.L. Direct inhibition of mitochondrial respiratory chain complex III by cell-permeable ceramide. J. Biol. Chem. 272:1998;24154-24158.
175. Degli Espoti M., McLennan H. Mitochondria and cells produce reactive oxygen species in virtual anaerobiosis: relevance to ceramide-induced apoptosis. FEBS Lett. 430:1998;338-342.
176. Richter C., Ghafourifar P. Ceramide induces cytochrome c release from isolated mitochondria. Biochem. Soc. Symp. 66:1999;27-31.
177. Podesser P.K., Schirnhofer J., Bernecker O.Y.et al. Optimizing ischemia/reperfusion in the failing rat heart: improved myocardial protection with acute ACE inhibition. Circulation. 106(suppl I):2002;I277-I283.